Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|8|824-833

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.8, 2010-12, pp. : 824-833

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer

By  

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 9, 2015-01 ,pp. : 804-815

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K Pathway Inhibitors: Better Not Left Alone

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 895-906

Bentham Science Publishers

Access to resources Recommend Favorite

The PI3K/Akt Pathway and Its Downstream Transcriptional Factors as Targets for Chemoprevention

By  

Current Cancer Drug Targets, Vol. 7, Iss. 4, 2007-06 ,pp. : 305-316

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 16, 2004-06 ,pp. : 1907-1914

Bentham Science Publishers

Access to resources Recommend Favorite